scholarly journals Mutational profile applicability in the prognosis of resected colorectal liver metastases beyond the classical clinical risk score

HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S351
Author(s):  
C. Dopazo-Taboada ◽  
T. Sauri ◽  
A. Herrando ◽  
J. Hernández ◽  
A. Vivancos ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Risk Score ◽  
Colorectal Liver Metastases ◽  
Clinical Risk Score ◽  
Clinical Risk

The metabolic clinical risk score (mCRS) as a new prognostic model for surgical decision in patients with colorectal liver metastases.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15094-e15094
Author(s):  
Ivan Duran Derijckere ◽  
Hugo Levillain ◽  
Ali Bohlok ◽  
Celine Mathey ◽  
Jonathan Nezri ◽  
...  
Keyword(s):  
High Risk ◽  
Liver Metastases ◽  
Risk Score ◽  
Fdg Pet ◽  
Colorectal Liver Metastases ◽  
Clinical Risk Score ◽  
Clinical Risk ◽  
Pet Ct ◽  
Selection For ◽  
Fdg Pet Ct

e15094 Background: Selection for surgery in patients with colorectal liver metastases (CRLM) remains poorly accurate. We evaluated if baseline metabolic characteristics of CRLM, as assessed by [18]-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18FDG-PET/CT), may predict the postoperative outcome in patients operated for CRLM. Methods: In a series of 450 patients operated for CRLM, we retrospectively identified 2 groups: The long-term survival (LTS), as defined by postoperative recurrence-free survival (RFS)≥5 years, and the early relapse groups (ER), as defined by RFS < 1 year. Clinicopathologic characteristics, Clinical Risk Score (CRS) and baseline 18FDG-PET/CT metabolic parameters were analyzed. Baseline 18FDG-PET/CT was performed at the time of diagnosis of CRLM, before any preoperative treatment. Low and high-risk CRS were defined by scores of 0 to 2 and 3 to 5, respectively. Metabolic CRS (mCRS) was implemented, using 1 additional point to the standard CRS when the highest tumor standardized uptake value (SUVmax) and normal liver mean SUV (SUVmean(liver)) ratio was > 4.3. Low and high-risk mCRS were defined by scores of 0 to 2 and 3 to 6, respectively. Results: We analyzed 53 patients. No difference was observed between LTS (n = 23) and ER (n = 30) groups for clinicopathologic parameters related to the primary tumor and CRLM, CRS and rates of low/high risk CRS. All metabolic parameters analyzed, including SUVmax and SUVpeak, at the exception of metabolic tumor volume, were significantly increased in ER group. Median SUVmax/SUVmean(liver) ratio was significantly increased in the ER vs LTS, respectively of 4.2 and 2.8 (p = 0.008). mCRS was significantly higher in ER as compared to LTS patients (p = 0.024), while 61% of the LTS patients had a low-risk mCRS and 73% of the ER patients had a high-risk mCRS (p = 0.023). Conclusions: Baseline 18FDG-PET/CT characteristics demonstrate an increased tumor glucose uptake in patients who rapidly recur after curative-intent surgery for CRLM. The introduction of these data into clinical risk model may represent a new tool to improve selection for surgery in patients with CRLM.

scholarly journals Validation of clinical risk score for colorectal liver metastases resected in a contemporary multicenter cohort

HPB ◽  
2017 ◽  
Vol 19 ◽  
pp. S66
Author(s):  
P. Beamish ◽  
M. Lemke ◽  
J. Li ◽  
E. Dixon ◽  
M.T. Abraham ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Risk Score ◽  
Colorectal Liver Metastases ◽  
Clinical Risk Score ◽  
Clinical Risk ◽  
Multicenter Cohort

scholarly journals Validation of clinical risk score for colorectal liver metastases resected in a contemporary multicenter cohort

HPB ◽  
2017 ◽  
Vol 19 (8) ◽  
pp. 675-681 ◽  
Author(s):  
Paul Beamish ◽  
Madeline Lemke ◽  
Jennifer Li ◽  
Elijah Dixon ◽  
Mauro T. Abraham ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Risk Score ◽  
Colorectal Liver Metastases ◽  
Clinical Risk Score ◽  
Clinical Risk ◽  
Multicenter Cohort

scholarly journals Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Nuh N Rahbari ◽  
Christoph Reissfelder ◽  
Henning Schulze-Bergkamen ◽  
Dirk Jäger ◽  
Markus W Büchler ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Liver Metastases ◽  
Risk Score ◽  
Predictive Value ◽  
Colorectal Liver Metastases ◽  
Clinical Risk Score ◽  
Clinical Risk

scholarly journals Is the Clinical Risk Score for Patients with Colorectal Liver Metastases Still Useable in the Era of Effective Neoadjuvant Chemotherapy?

2011 ◽  
Vol 18 (10) ◽  
pp. 2757-2763 ◽  
Author(s):  
Ninos Ayez ◽  
Zarina S. Lalmahomed ◽  
Anne E. M. van der Pool ◽  
Yvonne Vergouwe ◽  
Kees van Montfort ◽  
...  
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Liver Metastases ◽  
Risk Score ◽  
Colorectal Liver Metastases ◽  
Clinical Risk Score ◽  
Clinical Risk

scholarly journals Evolution of Surgical Treatment of Colorectal Liver Metastases in the Real World: Single Center Experience in 1212 Cases

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1178
Author(s):  
Francesca Ratti ◽  
Federica Cipriani ◽  
Guido Fiorentini ◽  
Valentina Burgio ◽  
Monica Ronzoni ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Risk Score ◽  
Colorectal Liver Metastases ◽  
Laparoscopic Approach ◽  
Clinical Risk Score ◽  
Single Center ◽  
Term Survival ◽  
Clinical Risk ◽  
Surgical Technical

Background: In recent years, the treatment of colorectal liver metastases (CRLM) has undergone significant evolution thanks to technical improvements as well as oncological advances, which have been the subject of targeted studies aimed at understanding the details of this heterogeneous disease. The purpose of this study is to put together pieces of this complex scenario by providing an overview of the evolution that has occurred in the context of a single center within a multidisciplinary management approach. Methods: Between 2005 and 2020, 1212 resections for CRLM were performed at the Hepatobiliary Surgery Division of San Raffaele Hospital, Milan. The series was divided into three historical periods, which were compared in terms of disease characteristics and short- and long-term outcomes: Period 1, 2005–2009 (293 cases); Period 2, 2010–2014 (353 cases); Period 3, 2015–2020 (566 cases). The trends for surgical technical complexity, oncological burden of the disease, use of the laparoscopic approach and use of techniques for hepatic hypertrophy were analyzed year by year. Uni- and multivariate analyses were performed to identify factors associated with inclusion to a laparoscopic approach and with long-term prognosis. Results: The number of resections performed over the years progressively increased, with an increase in the number of cases with a high Clinical Risk Score and a high profile of technical complexity. The proportion of cases performed laparoscopically increased, but less rapidly compared to other malignant tumors. The risk of postoperative morbidity and mortality was similar in the three analyzed periods. Long-term survival, stratified by Clinical Risk Score, improved in Period 3, while overall survival remained unchanged. Conclusion: The cultural background, the maturation of technical expertise and the consolidation of the multidisciplinary team have resulted in safe expansion of the possibility to offer a curative opportunity to patients, while continuously implementing into clinical practice evidence provided by the literature.

Sign in / Sign up

Export Citation Format

Share Document